Press release
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
- Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the
About this update from Incyte Corporation
[{"type":"text","content":"\n- Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021), held December 11–14, 2021 in Atlanta, Georgia and virtually.\n\n“We are excited for the opportunity to present, along with our partners, more than 35 abstracts and share progress from Incyte’s oncology portfolio at this year’s ASH meeting,” said Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. “The oral presentations, including new data from the CITADEL program evaluating parsaclisib in three types of lymphoma as well as results from the RE-MIND2 study of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, highlight the strength of our robust oncology portfolio and underscore our commitment to addressing urgent medical needs for people with cancer.”\n\nSelect key abstract presentations from Incyte-developed and partnered programs include:\n\nOral Presentations\n\nParsaclisib\n\nEfficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) (Abstract #44. Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma. Saturday, December 11, 9:45 a.m. ET)\n\nEfficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205) (Abstract #382. Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Front-line Induction Therapy and Novel Agents After Relapse. Sunday, December 12, 10:15 a.m. ET)\n\nEfficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma: Primary Analysis From a Phase 2 Study (CITADEL-203) (Abstract #813. Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Front-line Induction Therapy and Novel Agents After Relaps...